Published in J Cell Mol Med on April 01, 2012
Claudins and the modulation of tight junction permeability. Physiol Rev (2013) 2.05
Analysis of Snail-1, E-cadherin and claudin-1 expression in colorectal adenomas and carcinomas. Int J Mol Sci (2012) 0.89
Biphasic modulation of paracellular claudin-5 expression in mouse brain endothelial cells is mediated through the phosphoinositide-3-kinase/AKT pathway. J Pharmacol Exp Ther (2014) 0.82
Stromal Claudin14-heterozygosity, but not deletion, increases tumour blood leakage without affecting tumour growth. PLoS One (2013) 0.80
Gene expression profiling of the response to interferon beta in Epstein-Barr-transformed and primary B cells of patients with multiple sclerosis. PLoS One (2014) 0.78
TAP1 I333V gene polymorphism and type 1 diabetes mellitus: a meta-analysis of 2248 cases. J Cell Mol Med (2014) 0.77
Expression of tight junction protein claudin-1 in human crescentic glomerulonephritis. Int J Nephrol (2014) 0.77
Appearance of claudin-5(+) leukocytes in the central nervous system during neuroinflammation: a novel role for endothelial-derived extracellular vesicles. J Neuroinflammation (2016) 0.76
Leukocyte Gene Expression and Plasma Concentration in Multiple Sclerosis: Alteration of Transforming Growth Factor-βs, Claudin-11, and Matrix Metalloproteinase-2. Cell Mol Neurobiol (2016) 0.76
JAML mediates monocyte and CD8 T cell migration across the brain endothelium. Ann Clin Transl Neurol (2015) 0.76
Multiple signals at the extended 8p23 locus are associated with susceptibility to systemic lupus erythematosus. J Med Genet (2017) 0.75
Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25- LAP+ T cells. Nat Med (2006) 2.93
Childhood obesity. J Clin Endocrinol Metab (2004) 2.29
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol (2011) 2.19
Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol (2006) 1.61
Increased prevalence of microvascular complications in type 2 diabetes patients with the metabolic syndrome. Isr Med Assoc J (2006) 1.60
High frequency of pre-diabetes, undiagnosed diabetes and metabolic syndrome among overweight Arabs in Israel. Isr Med Assoc J (2005) 1.57
Multiple sclerosis frequency in Israel's diverse populations. Neurology (2006) 1.52
Impact of exposure to war stress on exacerbations of multiple sclerosis. Ann Neurol (2008) 1.49
Telemedicine for multiple sclerosis patients: assessment using Health Value Compass. Mult Scler (2011) 1.45
Prevention of type 1A diabetes: update. Isr Med Assoc J (2004) 1.38
Internet usage by patients with multiple sclerosis: implications to participatory medicine and personalized healthcare. Mult Scler Int (2010) 1.20
Regulation of endothelial matrix metalloproteinase-2 by hypoxia/reoxygenation. Circ Res (2002) 1.15
Improvement of islet function in a bioartificial pancreas by enhanced oxygen supply and growth hormone releasing hormone agonist. Proc Natl Acad Sci U S A (2012) 1.14
Mesenchymal stem cells as an immunomodulatory therapeutic strategy for autoimmune diseases. Autoimmun Rev (2011) 1.13
Virtual reality cues for improvement of gait in patients with multiple sclerosis. Neurology (2006) 1.11
Mutations in the glucocerebrosidase gene and Parkinson disease: phenotype-genotype correlation. Neurology (2005) 1.04
Laquinimod modulates B cells and their regulatory effects on T cells in multiple sclerosis. J Neuroimmunol (2012) 1.04
Enhanced oxygen supply improves islet viability in a new bioartificial pancreas. Cell Transplant (2012) 1.03
Home-based personalized cognitive training in MS patients: a study of adherence and cognitive performance. NeuroRehabilitation (2010) 1.02
Cathepsins (S and B) and their inhibitor Cystatin C in immune cells: modulation by interferon-β and role played in cell migration. J Neuroimmunol (2010) 1.02
Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype. Eur J Hum Genet (2002) 1.01
The ubiquitin-proteasome pathway regulates claudin 5 degradation. J Cell Biochem (2012) 0.99
Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis. J Neurol Sci (2006) 0.96
Sexual dysfunction in females with multiple sclerosis: quantitative sensory testing. Mult Scler (2007) 0.95
Hypoxia of endothelial cells leads to MMP-2-dependent survival and death. Am J Physiol Cell Physiol (2005) 0.95
Control of childhood congenital adrenal hyperplasia and sleep activity and quality with morning or evening glucocorticoid therapy. J Clin Endocrinol Metab (2008) 0.94
New immunosuppressive approaches: oral administration of CD3-specific antibody to treat autoimmunity. J Neurol Sci (2008) 0.93
Chronotherapy using corticosteroids for multiple sclerosis relapses. J Neurol Neurosurg Psychiatry (2006) 0.92
Melatonin dysregulation, sleep disturbances and fatigue in multiple sclerosis. J Neurol Sci (2011) 0.92
The role of IL-18 and IL-12 in the modulation of matrix metalloproteinases and their tissue inhibitors in monocytic cells. Int Immunol (2002) 0.91
Treatment of congenital hyperinsulinism with lanreotide acetate (Somatuline Autogel). J Clin Endocrinol Metab (2011) 0.91
Auditory feedback control for improvement of gait in patients with Multiple Sclerosis. J Neurol Sci (2007) 0.89
Detection of multiple sclerosis from exhaled breath using bilayers of polycyclic aromatic hydrocarbons and single-wall carbon nanotubes. ACS Chem Neurosci (2011) 0.89
Different contributions of insulin resistance and beta-cell dysfunction in overweight Israeli Arabs with IFG and IGT. Diabetes Metab Res Rev (2006) 0.88
Metabolic evidence for impaired 17alpha-hydroxylase activity in a kindred bearing the E305G mutation for isolate 17,20-lyase activity. Eur J Endocrinol (2008) 0.88
Neuropsychological profile of DYT1 dystonia. Mov Disord (2006) 0.88
Translation towards personalized medicine in Multiple Sclerosis. J Neurol Sci (2008) 0.87
The efficacy of an immunoisolating membrane system for islet xenotransplantation in minipigs. PLoS One (2013) 0.87
Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells. J Neuroimmunol (2005) 0.87
Modulation of monocytes matrix metalloproteinase-2, MT1-MMP and TIMP-2 by interferon-gamma and -beta: implications to multiple sclerosis. J Neuroimmunol (2002) 0.86
Interferon-beta induces distinct gene expression response patterns in human monocytes versus T cells. PLoS One (2013) 0.84
Patients with multiple sclerosis in a war zone: coping strategies associated with reduced risk for relapse. Mult Scler (2010) 0.84
Cathepsins and their endogenous inhibitors cystatins: expression and modulation in multiple sclerosis. J Cell Mol Med (2011) 0.84
Brain responses to verbal stimuli among multiple sclerosis patients with pseudobulbar affect. J Neurol Sci (2008) 0.84
Participatory medicine and patient empowerment towards personalized healthcare in multiple sclerosis. Expert Rev Neurother (2012) 0.84
In vitro induction of regulatory T cells by anti-CD3 antibody in humans. J Autoimmun (2008) 0.84
Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers. Pharmacogenet Genomics (2007) 0.84
Photosynthetic oxygen generator for bioartificial pancreas. Tissue Eng (2006) 0.84
Emotional responses of children and adolescents to parents with multiple sclerosis. Mult Scler (2005) 0.83
TH1/TH2 cytokine secretion of first degree relatives of T1DM patients. Cytokine (2005) 0.83
Sensitivity of HaCat keratinocytes to diabetogenic toxins. Biochem Pharmacol (2002) 0.83
Emerging therapeutic targets in multiple sclerosis. Curr Opin Neurol (2006) 0.83
Bio-markers of disease activity and response to therapy in multiple sclerosis. Clin Neurol Neurosurg (2004) 0.83
Goal disengagement and goal re-engagement among multiple sclerosis patients: relationship to well-being and illness representation. Psychol Health (2009) 0.83
Celiac disease and HLA in a Bedouin kindred. Hum Immunol (2006) 0.82
The 'immunological-synapse' at its APC side in relapsing and secondary-progressive multiple sclerosis: modulation by interferon-beta. J Neuroimmunol (2003) 0.82
Cytokine-mediated modulation of MMPs and TIMPs in multipotential neural precursor cells. J Neuroimmunol (2006) 0.82
The analgesic effect of botulinum-toxin A on postwhiplash neck pain. Clin J Pain (2008) 0.82
Expression of matrix metalloproteinases, sICAM-1 and IL-8 in CSF from children with meningitis. J Neurol Sci (2003) 0.82
Different susceptibility of rat pancreatic alpha and beta cells to hypoxia. Histochem Cell Biol (2012) 0.82
T cells from autoimmune patients display reduced sensitivity to immunoregulation by mesenchymal stem cells: role of IL-2. Autoimmun Rev (2013) 0.81
Pharmacogenetic Development of Personalized Medicine: Multiple Sclerosis Treatment as a Model. Drug News Perspect (2002) 0.81
Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis. Curr Med Res Opin (2007) 0.81
Mediterranean weather conditions and exacerbations of multiple sclerosis. Neuroepidemiology (2010) 0.81
A novel approach of local corticosteroid injection for the treatment of carpal tunnel syndrome. Clin Rheumatol (2005) 0.80
Involvement of phosphodiesterases in autoimmune diseases. J Neuroimmunol (2010) 0.80
Modulation of matrix metalloproteinase-9 (MMP-9) secretion in B lymphopoiesis. Int Immunol (2006) 0.80
Lengthening temporalis myoplasty for facial palsy reanimation. Isr Med Assoc J (2007) 0.79
The novel multifunctional, iron-chelating drugs M30 and HLA20 protect pancreatic beta-cell lines from oxidative stress damage. J Pharmacol Exp Ther (2010) 0.79
Multiple sclerosis pharmacogenetics: personalized approach towards tailored therapeutics. EPMA J (2010) 0.79
Induction of beta-cell resistance to hypoxia and technologies for oxygen delivery to transplanted pancreatic islets. Diabetes Metab Res Rev (2012) 0.79
Junctional epidermolysis bullosa in the Middle East: clinical and genetic studies in a series of consanguineous families. J Am Acad Dermatol (2002) 0.79
Impact of gastric banding on plasma adiponectin levels. Obes Surg (2006) 0.79
Cognitive and developmental outcome of conservatively treated children with congenital hyperinsulinism. J Pediatr Endocrinol Metab (2013) 0.79
Vitamin D supplementation for patients with multiple sclerosis treated with interferon-beta: a randomized controlled trial assessing the effect on flu-like symptoms and immunomodulatory properties. BMC Neurol (2013) 0.78
Matrix metalloproteinase-9, its tissue inhibitor(TIMP)-1 and CRP in Alzheimer's disease. Eur Neurol (2004) 0.78
Essential Tremor Prevalence is Low in the Druze Population in Northern Israel. Tremor Other Hyperkinet Mov (N Y) (2012) 0.78
Toxin-based selection of insulin-producing cells with improved defense properties for islet cell transplantation. Diabetes Metab Res Rev (2005) 0.78
The influence of vitamin D supplementation on melatonin status in patients with multiple sclerosis. Brain Behav Immun (2013) 0.78
Inorganic lead enhances cytokine-induced elevation of matrix metalloproteinase MMP-9 expression in glial cells. J Neuroimmunol (2002) 0.78
Glide-symmetric locomotion reinforcement in patients with multiple sclerosis by visual feedback. Disabil Rehabil Assist Technol (2010) 0.78
Immunological indicators of disease activity and prognosis in multiple sclerosis. Curr Opin Neurol (2002) 0.77